![Page 1: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/1.jpg)
11
Nanotechnology and the Food and Drug Administration:
Science and Policy
Richard Canady, PhD DABTFood and Drug Administration
First Annual Safety for Success Dialogue, European Commission
October 25, 2007
![Page 2: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/2.jpg)
22
FDA MISSION
The FDA is responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation.
The FDA is also responsible for advancing the public health by helping to speed innovations that make medicines and foods more effective, safer, and more affordable; and helping the public get the accurate, science-based information they need to use medicines and foods to improve their health.
![Page 3: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/3.jpg)
3
FDA REGULATED PRODUCTS• Animal feed• Foods
– Not meat or poultry– Bottled water– Wine (<7% alcohol)– Infant formula
• Food additives– Colors– Food containers
• Cosmetics• Dietary Supplements
![Page 4: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/4.jpg)
4
• Pharmaceuticals– Human– Animal– Tamper resistant
packaging• Medical devices• Radiation emitting
electronic products• Vaccines• Blood products• Tissues• Sterilants• Counter-terrorism products
![Page 5: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/5.jpg)
5
NANOSCALE MATERIALSFDA STATUS
• Regulation specific to product classes by statute
• Range of regulatory authorities• Review of products, not technology• Adaptable: new knowledge may
lead to change
![Page 6: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/6.jpg)
66
FDA NANOTECHNOLOGY TASK FORCE
• Encourage development of safe and effective products
• Address knowledge or policy gaps
• Guide science and technology
• Assess current state of science
• Strengthen collaboration with federal agencies
![Page 7: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/7.jpg)
7
Nanotechnology Task Force Bottom Lines
1. Nanoscale materials could be used in most product types regulated by FDA.
2. Nanoscale materials present challenges similar to other emerging technologies.
3. The fact that safety and efficacy can vary with size can complicate the challenges.
4. Steps should be taken to better inform FDA reviewers and industry about what is known, needed, and expected.
![Page 8: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/8.jpg)
8
Size can complicate challenges
• Measurement– What to measure– How
• Product consistency• Assays
– Validity– Utility
• Definition of impurity
![Page 9: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/9.jpg)
99
Definition issue
• No definition offered or used in FDA Task Force report
• Broad inclusive approach taken
• Continue to consider importance of material size and state of the science
• At some point it may be productive to tailor definitions to specific product areas
![Page 10: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/10.jpg)
10
Ren
al C
lear
ance
Bili
ary
Cle
aran
ce ?
Cytotoxicity(Surface Reactivity) RES
Recognition
(EPR Effect)
Size(Rigid Core)
Solu
bilit
y
Zeta
Pot
entia
l(+)
(–)
0
Low
High
1 nm 220 nm
Nanoparticle Biocompatibility
Cytotoxicity
Dose (mg/mL)
% C
ontr
ol
?
Trends: Biocompatibility Trends: Biocompatibility Trends: Biocompatibility
Source: Scott McNeil, NCL
![Page 11: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/11.jpg)
11
State of the Science
Size and functionalization of particles can affect biological interaction
– but not always– and not always in ways we think it
will
![Page 12: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/12.jpg)
12
State of the Science
If all nanoscale materials are compared to all non-nanoscale materials,
whether larger or smaller,
it is not apparent that the nanoscale materials as a group would have more inherent hazard.
![Page 13: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/13.jpg)
13
SCIENCE RECOMMENDATIONS
Regarding understanding biological interactions
– Promote/participate in developing more knowledge about
• biological interactions• detection and measurement
– Build in-house expertise and infrastructure to share and leverage knowledge
– Ensure Agency-wide regulatory-science coordination for nanoscale materials
![Page 14: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/14.jpg)
14
SCIENCE RECOMMENDATIONS
Regarding adequacy of testing approaches
– Evaluate adequacy of testing approaches to assess safety, effectiveness, and quality of products with nanoscale materials
– Promote/participate in the development of • characterization methods and standards for
nanoscale materials; and• models for the behavior of nanoscale particles in-
vitro and in-vivo.
![Page 15: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/15.jpg)
15
Regulatory Policy Issues Addressed by the FDA Task Force Report
• Ability to Identify Products that Contain Nanoscale Materials
• Authority Regarding Evaluation of Safety and Effectiveness
• Permissible and Mandatory Labeling
• National Environmental Policy Act
![Page 16: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/16.jpg)
16
Identification of Products Containing Nanomaterials
FDA’s authority to obtain information about particle size differs depending on whether products are subject to premarket authorization
– Comprehensive for products subject to premarket authorization
• Prescription human and animal drugs, biologics, new dietary ingredients
– More limited for products not subject to premarket authorization
• Conventional foods, cosmetics, dietary supplements
– Some products fall into both categories• Devices, OTC monograph drugs, GRAS food ingredients,
food and color additives
![Page 17: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/17.jpg)
17
Identification of Products Containing Nanomaterials
Recommendations– Premarket Authorization
• Issue guidance recommending that sponsors identify particle size of small particle materials in premarket submissions
– No Premarket Authorization• When warranted, request data on particle size as
part of rulemaking process used to establish or amend OTC drug monographs
![Page 18: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/18.jpg)
18
Ensure Safety
FDA’s authority to obtain information about safety and effectiveness differs depending on whether products are subject to premarket authorization
– Comprehensive for products subject to premarket authorization
– Cannot require submission of information when products are not subject to premarket authorization, but manufacturers are still responsible for ensuring the safety of their products
– Presence of nanoscale materials may change regulatory status
![Page 19: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/19.jpg)
19
Ensure SafetyRecommendations• Issue calls for safety data• Issue guidance on
– Manufacturing– GRAS food ingredients – Food and color additives– Devices – Cosmetics– Dietary supplements
![Page 20: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/20.jpg)
20
Labeling
• Labeling of FDA-regulated products must be truthful and not misleading, and contain material information
• As with any product, we do not require the inclusion in labeling of information that is not material nor permit the inclusion of information that would make the labeling false or misleading
• Current state of the science does not indicate “all nanotech” safety concerns
![Page 21: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/21.jpg)
21
Labeling
RecommendationAddress on a product-by-product basis
whether labeling must or may contain information on the use of nanomaterials
![Page 22: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/22.jpg)
22
National Environmental Policy Act (NEPA)• NEPA requires federal agencies to consider
the environmental effects of proposed major actions
• Agencies can establish categorical exclusions for categories of actions that do not have a significant effect on the environment
• But procedures must be established to recognize extraordinary circumstances when a normally excluded action may have a significant environmental effect
![Page 23: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/23.jpg)
23
NEPARecommendations
– Consider on a product-by-product basis whether an FDA-regulated product containing nanomaterials qualifies for an existing categorical exclusion or whether extraordinary circumstances exist
– Designate a lead to coordinate the agency’s approach to its obligations under NEPA regarding nanotechnology
![Page 24: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/24.jpg)
24
Research/data development
• FDA research database online soon
• National Toxicology Program
• Participation in White House National Science and Technology Council’s research priorities effort
• Participation in Organization of Economic Cooperation and Development working parties data development
• Alliance for NanoHealth – FDA workshop on critical path issues
![Page 25: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/25.jpg)
25
Bilateral Cooperation on Nanotechnology Issues• FDA cooperates bilaterally with many
international regulatory partners – see http://www.fda.gov/oia/default.htm– often supported by confidentiality arrangement
allowing the sharing of non-public information• FDA works together with DG-Enterprise, DG-
SANCO, DG-Research, EFSA and EMEA• Transatlantic Economic Cooperation agreement
includes nanotechnology– focus is on communication and research
![Page 26: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/26.jpg)
26
Multilateral Cooperation on Nanotechnology
• OECD– Working Party on Manufactured
Nanomaterials
– Working Party on Nanotechnology
• ISO TC229
![Page 27: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/27.jpg)
27
CONCLUSIONS
• No new regulation proposed
• FDA regulates a range of potential nanoscale material products using range of authorities
• Premarket authority provides comprehensive approach to evaluating safety, effectiveness, quality of products
• Products not subject to premarket authority do not have the same level of information available to FDA
![Page 28: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/28.jpg)
28
CONCLUSIONS (cont’d)
• Task force recommends issuance of guidances and requests for data with public input
• FDA will continue to review products on case-by-case basis
• FDA continues to stress the importance of early communication with industry
• FDA is seeking to increase data availability and expertise to facilitate review of products.
![Page 30: Nanotechnology and the Food and Drug Administration ...ec.europa.eu/health/ph_risk/committees/documents/ev...2007/10/25 · 1. Nanoscale materials could be used in most product types](https://reader033.vdocuments.us/reader033/viewer/2022060600/605488c0112c4740f8032c94/html5/thumbnails/30.jpg)
This paper was produced for a meeting organized by Health & Consumer Protection DG and represents the views of its author on thesubject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission's or Health & Consumer Protection DG's views. The European Commission does not guarantee the accuracy of the dataincluded in this paper, nor does it accept responsibility for any use made thereof.